Study guide
1.3 Diabetes Mellitus in Pregnancy
NCC Inpatient Obstetric Nursing RNC-OB
Track your progress as you read
Finished sections get a check mark.
1 Chapter 0: Introduction & How to Use This Guide
0.1 About the RNC-OB Credential & Exam Blueprint 0.2 How to Use This Study Guide & Clinical Learning Methodology
2 Chapter 1: Pregnancy Complications — Maternal Medical Conditions
1.1 Hypertensive Disorders of Pregnancy 1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy 1.3 Diabetes Mellitus in Pregnancy 1.4 Maternal Cardiac and Respiratory Disorders 1.5 Infectious Diseases in Inpatient Obstetrics 1.6 Hematologic, Endocrine, Connective Tissue & Other Systemic Disorders
3 Chapter 2: Pregnancy Complications — Preterm Labor, Multiple Gestation, Placental & Fetal Disorders
2.1 Psychosocial Disorders, Substance Use & Environmental Exposures 2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection 2.3 Multiple Gestation: Placentation, Chorionicity & Complications 2.4 Placental Disorders: Previa, Abruption, Vasa Previa & PAS 2.5 Fetal Growth Disorders & Amniotic Fluid Complications
4 Chapter 3: Antenatal Fetal Assessment & Surveillance
3.1 Antenatal Testing Methods & Indications for Fetal Surveillance 3.2 Nonstress Test (NST), Contraction Stress Test (CST) & Biophysical Profile (BPP) 3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound) 3.4 Fetal Oxygenation Physiology & Acid-Base Regulation 3.5 Umbilical Cord Blood Gas Collection & Clinical Interpretation
5 Chapter 4: Fetal Assessment & Electronic Fetal Monitoring (EFM)
4.1 NICHD Electronic Fetal Monitoring Terminology & Baseline Features 4.2 FHR Decelerations, Acceleration Patterns & Uterine Activity 4.3 The NICHD Three-Tier Fetal Heart Rate Classification System 4.4 Intrauterine Resuscitation & Clinical Action Protocols 4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation
6 Chapter 5: Labor & Birth Physiology — Mechanics, Cardinal Movements, Stages & Support
5.1 Physiology of Labor & Uterine Mechanics 5.2 Pelvic Anatomy, Fetal Lie, Presentation & Cardinal Movements of Labor 5.3 Stages of Labor, Cervical Dilatation Dynamics & Progression Guidelines 5.4 Intrapartum Admission Assessment, Obstetric Triage & Membrane Rupture Evaluation 5.5 Labor Support, Non-Pharmacologic Pain Management & Physiologic Birth Practices
7 Chapter 6: Labor & Birth Interventions — Cervical Ripening, Induction, Pain Management & Anesthesia
6.1 Bishop Scoring, Pre-Induction Cervical Ripening & Mechanical Methods 6.2 Oxytocin Administration, Titration Protocols & Uterine Tachysystole Management 6.3 Nonpharmacologic Comfort & Labor Pain Management Strategies 6.4 Systemic Opioid Analgesia & Inhaled Nitrous Oxide 6.5 Neuraxial Analgesia, Spinal/Epidural Complications & General Anesthesia
8 Chapter 7: Labor & Birth — Operative Deliveries, TOLAC/VBAC & Special Intrapartum Procedures
7.1 External Cephalic Version (ECV) & Malpresentation Management 7.2 Operative Vaginal Delivery: Vacuum Extraction & Forceps-Assisted Birth 7.3 Cesarean Delivery: Surgical Indications, Intraoperative Management & PACU Recovery 7.4 Trial of Labor After Cesarean (TOLAC) & Vaginal Birth After Cesarean (VBAC) 7.5 Special Intrapartum Procedures: Amniotomy, Amnioinfusion, Cervical Ripening & Labor Augmentation
9 Chapter 8: Obstetric Emergencies & Critical Care
8.1 Shoulder Dystocia Management & HELPERR Protocol 8.2 Umbilical Cord Prolapse & Feto-Vascular Emergencies 8.3 Uterine Rupture & Acute Uterine Inversion 8.4 Amniotic Fluid Embolism (Anaphylactoid Syndrome of Pregnancy) 8.5 Intraamniotic Infection (Chorioamnionitis) & Maternal Sepsis
10 Chapter 9: Postpartum Physiology & Immediate Recovery Care
9.1 Postpartum Physiologic Changes & Maternal Systemic Adaptations 9.2 Fourth Stage of Labor & Immediate Recovery Care 9.3 Routine Postpartum Nursing Assessment & Clinical Care (BUBBLE-HE) 9.4 Rh Isoimmunization, Alloimmunization & Postpartum Immunizations 9.5 Postpartum Discharge Teaching, Warning Signs & Maternal Safety
11 Chapter 10: Postpartum Adaptation, Hemorrhage & Clinical Complications
10.1 Postpartum Hemorrhage: Definition, Risk Stratification, 4 Ts, QBL & Pharmacotherapy 10.2 Postpartum Infections: Endometritis, Wound Infections, Sepsis & Postpartum Pyrexia 10.3 Thromboembolic Disorders: DVT, Pulmonary Embolism & Septic Pelvic Thrombophlebitis 10.4 Perinatal Mood & Anxiety Disorders: Postpartum Blues, PPD, Anxiety & Postpartum Psychosis 10.5 Lactation Physiology, Breastfeeding Complications, Engorgement & Medication Safety
12 Chapter 11: Newborn Care, Transition & Clinical Assessment
11.1 Neonatal Physiologic Transition & Cardiorespiratory Adaptation 11.2 Immediate Newborn Care, Apgar Scoring & Delivery Room Stabilization 11.3 Newborn Thermoregulation & Pathophysiology of Cold Stress 11.4 Gestational Age & Neonatal Growth Assessment 11.5 Comprehensive Newborn Head-to-Toe Examination & Normal Variants
13 Chapter 12: Newborn Complications, Resuscitation & High-Acuity Management
12.1 Neonatal Resuscitation Program (NRP 8th Edition) & Delivery Room Resuscitation 12.2 Neonatal Glucose Homeostasis, Hypoglycemia Screening & Clinical Management 12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols 12.4 Neonatal Respiratory Distress: TTN, RDS, Meconium Aspiration & Persistent Pulmonary Hypertension (PPHN) 12.5 Neonatal Sepsis, Congenital Infections & Neonatal Abstinence Syndrome (NAS/NOWS)
14 Chapter 13: Professional Practice, Legal-Ethical Frameworks, Patient Safety & Quality Improvement
13.1 Legal Aspects of Perinatal Nursing & High-Risk Documentation Standards 13.2 Ethical Principles in Perinatal Care & Maternal-Fetal Conflicts 13.3 Quality Improvement, Perinatal Safety Initiatives & AIM Bundles 13.4 Patient Safety Culture, Team Communication & Clinical Escalation 13.5 Evidence-Based Practice, Research Utilization & Perinatal Guidelines
1.3 Diabetes Mellitus in Pregnancy
Key Takeaways Explain This Topic AI
Gestational Diabetes Mellitus (GDM) is diagnosed using either the two-step strategy (50g 1-hour screen ≥130-140 mg/dL followed by 100g 3-hour OGTT meeting ≥2 Carpenter-Coustan thresholds: Fasting ≥95, 1-hr ≥180, 2-hr ≥155, 3-hr ≥140 mg/dL) or the one-step 75g 2-hour OGTT (IADPSG criteria).
Target glycemic thresholds during pregnancy are: Fasting blood glucose <95 mg/dL, 1-hour postprandial <140 mg/dL, 2-hour postprandial <120 mg/dL, and HbA1c <6.0% (target <6.5% if hypoglycemia risk).
Intrapartum blood glucose must be maintained strictly between 70 and 110 mg/dL (or <120 mg/dL) using hourly capillary checks and dual IV infusions (regular insulin infusion and 5% dextrose infusion) to prevent intrapartum fetal hyperglycemia and neonatal rebound hypoglycemia.
Diabetic Ketoacidosis (DKA) in pregnancy can manifest as euglycemic DKA (blood glucose <200 mg/dL) due to accelerated maternal starvation, placental glucose consumption, and increased renal glycosuria; initial management requires isotonic crystalloid resuscitation (500-1,000 mL/hr for the first 2-4 hours, adjusted with obstetric input), IV regular insulin infusion, and potassium repletion (insulin delayed while K+ <3.5 mEq/L).
Maternal hyperglycemia during organogenesis (weeks 3-8) in pregestational diabetes carries a high risk of congenital malformations, notably caudal regression syndrome (sacral agenesis), transposition of great vessels, and neural tube defects; late-pregnancy hyperinsulinemia drives asymmetric macrosomia and delayed pulmonary surfactant synthesis.
Last updated: October 2026
Classification and Pathophysiology of Diabetes in Pregnancy
Carbohydrate intolerance is one of the most common medical complications of pregnancy, affecting approximately 7% to 10% of all gestations. Diabetes in pregnancy is broadly classified into two major categories:
Pre-existing (Pregestational) Diabetes: Type 1 diabetes mellitus (autoimmune beta-cell destruction resulting in absolute insulin deficiency) or Type 2 diabetes mellitus (progressive insulin secretory defect on the background of chronic insulin resistance) diagnosed prior to conception or during the first trimester (HbA1c ≥6.5% or fasting plasma glucose ≥126 mg/dL).
Gestational Diabetes Mellitus (GDM): Carbohydrate intolerance with onset or first recognition during the second or third trimester of pregnancy. GDM is further subclassified into:
Class A1 (Diet-Controlled): Normal fasting glucose (<95 mg/dL) and postprandial glucose levels maintained strictly through medical nutrition therapy (MNT) and physical activity.
Class A2 (Medication-Requiring): Abnormal fasting or postprandial glucose levels requiring pharmacotherapy (insulin or oral hypoglycemics) to achieve euglycemia.
Endocrine Physiology of Pregnancy
Normal pregnancy is characterized by profound metabolic adaptations designed to ensure a constant supply of glucose and amino acids to the developing fetus:
First Trimester (Anabolic Phase): Elevated maternal estrogen and progesterone stimulate maternal pancreatic beta-cell hyperplasia, increasing insulin sensitivity and glycogen storage. Maternal fasting glucose levels are lower than in non-pregnant states (often 70–80 mg/dL).
Second and Third Trimesters (Catabolic / Diabetogenic Phase): As the placenta expands, it secretes increasing quantities of counter-regulatory anti-insulin hormones, primarily Human Placental Lactogen (hPL / Human Chorionic Somatomammotropin) , human placental growth hormone (hPGH), progesterone, cortisol, prolactin, and tumor necrosis factor-alpha (TNF-α). These hormones induce peripheral insulin resistance (a 50% to 60% decrease in insulin sensitivity) , peaking between 24 and 28 weeks of gestation. In normal pregnancy, maternal pancreatic beta cells compensate by increasing insulin secretion 2- to 3-fold. In gestational diabetes, maternal beta cells fail to overcome this physiologic resistance, leading to maternal hyperglycemia. +-------------------------------------------------------------------------------------------------------------------+
| SCREENING & DIAGNOSTIC CRITERIA FOR GDM (24-28 WEEKS) |
+-------------------------------------------------------------------------------------------------------------------+
- |
- [ 50g 1-Hour Non-Fasting GLT Screen ]
- |
- +---------------------------------------+---------------------------------------+
- | |
- [ Glucose <130-140 mg/dL ] [ Glucose ≥130-140 mg/dL ]
- | |
- [ Normal / Negative ] +-----------------+-----------------+
- | |
- [ Glucose ≥200 mg/dL ] [ Glucose 130-199 mg/dL ]
- | |
- [ Diagnostic of GDM ] [ Perform 100g 3-Hour OGTT ]
- (No 3-hr OGTT needed) (Fasting overnight ≥8 hr)
- |
+------------------------------------------------------------------------------------------------------------------+
| 100g 3-Hour OGTT Diagnostic Thresholds (≥2 Abnormal Values Required for Diagnosis) |
| ---------------------------------------------------------------------------------------------------------------- |
- | Measurement Timepoint Carpenter-Coustan Criteria NDDG Criteria |
- | Fasting ≥95 mg/dL (5.3 mmol/L) ≥105 mg/dL (5.8 mmol/L) |
- | 1-Hour Post-Load ≥180 mg/dL (10.0 mmol/L) ≥190 mg/dL (10.6 mmol/L) |
- | 2-Hour Post-Load ≥155 mg/dL (8.6 mmol/L) ≥165 mg/dL (9.2 mmol/L) |
- | 3-Hour Post-Load ≥140 mg/dL (7.8 mmol/L) ≥145 mg/dL (8.0 mmol/L) |
+------------------------------------------------------------------------------------------------------------------+
Target Blood Glucose Levels and Antenatal Management
To minimize maternal and fetal complications, strict blood glucose targets are established for all pregnant women with pregestational or gestational diabetes:
- Assessment Timepoint Capillary Whole Blood Glucose Target (ACOG / ADA)
- Fasting Blood Glucose <95 mg/dL (5.3 mmol/L)
- 1-Hour Postprandial <140 mg/dL (7.8 mmol/L)
- 2-Hour Postprandial <120 mg/dL (6.7 mmol/L)
- Mean Daily Blood Glucose <100 mg/dL (5.6 mmol/L)
- Overnight / Pre-meal 60 to 99 mg/dL (3.3 to 5.5 mmol/L)
- Hemoglobin A1c <6.0% (<42 mmol/mol) (target <6.5% if hypoglycemia risk)
- Pharmacotherapy
Insulin (First-Line Gold Standard): Insulin does NOT cross the placenta and is the drug of choice. Regimens typically combine intermediate/long-acting basal insulin (NPH, Insulin Detemir, Insulin Glargine) with rapid-acting prandial insulin (Insulin Lispro, Insulin Aspart) administered before meals.
Oral Antihyperglycemic Agents (Second-Line):
Metformin: Crosses the placenta readily (fetal levels equal or exceed maternal levels). Associated with lower rates of maternal hypoglycemia and less gestational weight gain, but higher rates of preterm birth and unknown long-term offspring metabolic effects.
Glyburide (Sulfonylurea): Crosses the placenta; associated with higher rates of neonatal hypoglycemia, macrosomia, and hyperbilirubinemia compared to insulin.
Intrapartum Glycemic Control Protocol
Maternal hyperglycemia during labor stimulates the fetal pancreas to secrete massive amounts of insulin. Following delivery and sudden separation from the maternal glucose supply, the neonate's elevated circulating insulin levels induce rapid, severe rebound neonatal hypoglycemia .
Inpatient Intrapartum Nursing Protocol
Target Intrapartum Glycemic Range: Maintain maternal capillary blood glucose strictly between 70 and 110 mg/dL (or <120 mg/dL).
Monitoring Frequency: Measure capillary blood glucose every 1 hour during active labor or while on an IV insulin infusion (every 2 to 4 hours in early latent labor if diet-controlled).
Dual Infusion Setup (Insulin and Dextrose Lines):
Primary Line: 5% Dextrose in 0.9% Normal Saline ( D 5 N S D_5NS D 5 NS ) or 5% Dextrose in Lactated Ringer's ( D 5 L R D_5LR D 5 L R ) running at a constant rate of 100 to 125 mL/hour (provides 5–6 g glucose/hr for active uterine myometrial work).
Secondary Piggyback Line: Regular Human Insulin (100 units in 100 mL 0.9% Normal Saline = 1 unit/mL ) connected to the lowest port via an automated smart infusion pump. +-------------------------------------------------------------------------------------------------------------------+
| STANDARDIZED INTRAPARTUM IV REGULAR INSULIN TITRATION ALGORITHM |
+-------------------------------------------------------------------------------------------------------------------+
- Blood Glucose Level (mg/dL) IV Insulin Infusion Rate (units/hr) IV Fluid Maintenance Solution
- -------------------------- ----------------------------------- -----------------------------
- <70 mg/dL 0.0 units/hr (STOP infusion) Increase D5W to 150 mL/hr; recheck in 30 min
- 70 - 99 mg/dL 0.0 units/hr (Hold infusion) D5W or D5 1/2 NS at 100-125 mL/hr
- 100 - 119 mg/dL 0.5 units/hr D5 1/2 NS at 100 mL/hr
- 120 - 139 mg/dL 1.0 units/hr D5 1/2 NS at 100 mL/hr
- 140 - 159 mg/dL 1.5 units/hr Switch to Normal Saline (No Dextrose) @ 100 mL/hr
- 160 - 179 mg/dL 2.0 units/hr Normal Saline (No Dextrose) @ 100 mL/hr
- ≥180 mg/dL 2.5 - 3.0 units/hr (Notify Provider) Normal Saline (No Dextrose) @ 100 mL/hr
+-------------------------------------------------------------------------------------------------------------------+
Diabetic Ketoacidosis (DKA) in Pregnancy
Diabetic Ketoacidosis (DKA) is an extreme obstetric medical emergency carrying a maternal mortality of 1% to 3% and a fetal mortality rate of 15% to 35% . Pregnancy is an inherently ketogenic state due to accelerated starvation, increased lipolysis, reduced buffering capacity (physiologic respiratory alkalosis with low baseline bicarbonate [18–22 mEq/L]), and placental hormones.
Critical Clinical Pearl: Euglycemic DKA: In pregnant patients, DKA frequently develops at much lower blood glucose concentrations than in non-pregnant individuals—frequently presenting with blood glucose levels <200 mg/dL (and even <150 mg/dL). This occurs because of continuous transplacental glucose siphonage by the fetus and placenta, expanded maternal intravascular volume, and marked glycosuria from increased GFR.
Clinical Presentation and Diagnostic Criteria
Triggers: Infection (chorioamnionitis, pyelonephritis, influenza), non-compliance or pump failure, beta-mimetic tocolytic therapy (terbutaline), antenatal corticosteroid administration (betamethasone), or vomiting/starvation.
Signs & Symptoms: Nausea, vomiting, abdominal pain, Kussmaul respirations (rapid, deep breathing to blow off C O 2 CO_2 C O 2 ), fruity acetone breath odor, altered sensorium, and maternal tachycardia.
Laboratory Profile:
- Arterial pH <7.30 (or venous pH <7.25)
- Serum Bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ) <15 mEq/L
Elevated Anion Gap: [ N a + ] − ( [ C l − ] + [ H C O 3 − ] ) > 12 mEq/L [Na^+] - ([Cl^-] + [HCO_3^-]) > 12\text{ mEq/L} [ N a + ] − ([ C l − ] + [ H C O 3 − ]) > 12 mEq/L
Positive serum and urine ketones (elevated beta-hydroxybutyrate >3.0 mmol/L)
Inpatient DKA Resuscitation Protocol +-------------------------------------------------------------------------------------------------------------------+
| STEP-BY-STEP INTRAPARTUM DKA PROTOCOL |
+-------------------------------------------------------------------------------------------------------------------+
- |
- [ 1. AGGRESSIVE FLUID RESUSCITATION ]
- Hours 1-4: 500 to 1,000 mL/hr of isotonic crystalloid (2024 adult consensus)
- Then adjust fluid type and rate to hydration status and sodium
- Add 5-10% dextrose when Blood Glucose falls below 250 mg/dL
- |
- [ 2. INTRAVENOUS REGULAR INSULIN INFUSION ]
- Initial IV Bolus: 0.1 units/kg (optional)
- Continuous IV Infusion: 0.1 units/kg/hour
- Goal: Reduce glucose by 50 to 75 mg/dL per hour
- Maintain insulin infusion until ketoacidosis resolves
- (ketone <0.6 mmol/L and pH >=7.3 or HCO3 >=18)
- |
- [ 3. POTASSIUM REPLACEMENT ]
- If K+ >5.0 mEq/L: Do NOT give potassium until K+ <5.0;
- recheck 2 h after insulin, then q4h
- If K+ 3.5 - 5.0 mEq/L: Add 20 - 30 mEq KCl per liter of IV fluid
- once urine output verified
- If K+ <3.5 mEq/L: HOLD insulin; give about 10 mEq/hr until K+ >3.5 mEq/L
- (prevents cardiac arrest)
- |
- [ 4. FETAL SURVEILLANCE & RESUSCITATION ]
- Expect transient Category II/III patterns
- (late decelerations, minimal variability)
- DO NOT perform emergency delivery during active ketoacidosis
- FHR tracing recovers as maternal acidosis and volume deficits normalize
+-------------------------------------------------------------------------------------------------------------------+
Maternal, Fetal, and Neonatal Complications +-------------------------------------------------------------------------------------------------------------------+
| PATHOPHYSIOLOGIC EFFECTS OF MATERNAL HYPERGLYCEMIA |
+-------------------------------------------------------------------------------------------------------------------+
- MATERNAL HYPERGLYCEMIA FETAL CONSEQUENCES NEONATAL MORBIDITIES
- -------------------- ------------------ --------------------
- Glucose crosses placenta Fetal Hyperglycemia Neonatal Hypoglycemia (<40 mg/dL)
- (Insulin does NOT cross) --> Fetal Pancreatic Hyperplasia --> Respiratory Distress Syndrome (RDS)
- Excessive Fetal Insulin Polycythemia & Hyperbilirubinemia
- Asymmetric Macrosomia (>4500g) Hypocalcemia & Hypomagnesemia
- Polyhydramnios (osmotic diuresis) Hypertrophic Cardiomyopathy
+-------------------------------------------------------------------------------------------------------------------+
Maternal Complications
Preeclampsia and gestational hypertension (3- to 4-fold increased risk).
Diabetic retinopathy progression and worsening diabetic nephropathy.
Polyhydramnios (Amniotic Fluid Index [AFI] ≥24 cm or Single Deepest Pocket [SDP] ≥8 cm) secondary to fetal polyuria, increasing the risk of preterm labor, placental abruption, and postpartum hemorrhage.
Operative vaginal delivery, severe perineal lacerations (3rd/4th degree), and primary cesarean delivery.
Fetal Malformations and Organopathy
Congenital Anomalies (Unique to Pregestational Diabetes with Periconceptional Hyperglycemia):
Caudal Regression Syndrome (Sacral Agenesis): 200-fold increase; highly specific for pregestational diabetes.
Congenital Heart Defects: Transposition of the great vessels, Ventricular Septal Defect (VSD), coarctation of the aorta.
Central Nervous System: Anencephaly, spina bifida, hydrocephalus.
Fetal Growth Derangements:
Asymmetric Macrosomia (Pedersen Hypothesis): Excess maternal glucose traverses the placenta via facilitated diffusion. The fetal pancreas responds with beta-cell hyperplasia and hyperinsulinemia. Fetal insulin acts as a potent growth hormone, stimulating lipogenesis and protein synthesis, resulting in disproportionate fat deposition over the shoulders and torso (shoulder-to-head disproportion), predisposing to shoulder dystocia .
Delayed Fetal Lung Maturity: Fetal hyperinsulinemia directly blocks the inductive actions of cortisol on alveolar type II pneumocytes, inhibiting the transcription of surfactant proteins (SP-A, SP-B) and delaying lecithin synthesis. Consequently, infants of diabetic mothers are at high risk for Respiratory Distress Syndrome (RDS) even at term (37–38 weeks).
Delivery Timing and Postpartum Management
Delivery Timing Guidelines:
GDM Class A1 (Diet-controlled): Expectant management with planned delivery at 39 0/7 to 40 6/7 weeks .
GDM Class A2 (Medication-requiring): Planned delivery at 39 0/7 to 39 6/7 weeks .
Poorly Controlled GDM / Pregestational Diabetes with Vascular Disease: Planned delivery at 36 0/7 to 38 6/7 weeks .
Estimated Fetal Weight (EFW) Threshold for Cesarean Delivery: Offer elective cesarean delivery if EFW is >4,500 grams in diabetic gravidas (compared to >5,000 g in non-diabetic gravidas) to prevent catastrophic shoulder dystocia and brachial plexus injury.
Postpartum Insulin Management:
Following the expulsion of the placenta, circulating levels of hPL, progesterone, and cortisol drop precipitously within hours, abruptly reversing insulin resistance.
In patients with GDM: Discontinue all insulin and oral hypoglycemics immediately upon delivery; monitor postpartum fasting glucose.
In patients with Type 1 Diabetes: Immediately reduce baseline pre-pregnancy insulin doses by 50% or initiate a low-dose subcutaneous sliding scale to prevent severe postpartum hypoglycemia.
Postpartum Screening for GDM: Perform a 75g 2-hour oral glucose tolerance test (OGTT) at 4 to 12 weeks postpartum to screen for persistent pre-diabetes or overt Type 2 diabetes.